Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
McKinsey
Johnson and Johnson
Colorcon
Harvard Business School

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Patent: 10,265,291

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,265,291
Title:Disulfur bridge linkers for conjugation of a cell-binding molecule
Abstract: The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.
Inventor(s): Zhao; Robert Yongxin (Lexington, MA)
Assignee: HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN)
Application Number:15/431,154
Patent Claims:see list of patent claims

Details for Patent 10,265,291

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX Orphan search
Janssen Biotech STELARA ustekinumab INJECTABLE;INJECTION 761044 001 2019-11-07   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX search
Genentech Inc TECENTRIQ atezolizumab INJECTABLE; INJECTION 761041 001 2016-10-18   Start Trial HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) 2035-07-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Baxter
Dow
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.